Bharat Biotech has teamed up with Alopexx Inc to co-develop and market the broad-spectrum antimicrobial vaccine AV0328 in India and other low-income areas. The vaccine targets poly N-acetyl glucosamine found on various pathogens. Pre-clinical studies showed its effectiveness against over 15 pathogens, and a phase I trial confirmed its safety.
Related Posts
Great news! IIT graduates see rise in high-paying salary offers based in India; packages comparable to international salaries
IIT graduates are receiving increasingly high domestic salary offers, ranging from Rs 65 lakh to Rs 1.65 crore, from firms specializing in algorithmic trading, data […]
Hyundai aims to raise up to $3.3 billion in record India IPO
Hyundai Motor Co aims to raise up to $3.3 billion through an IPO of its Indian subsidiary, setting a record in the country. The IPO […]